ATE449174T1 - Neue peptide - Google Patents

Neue peptide

Info

Publication number
ATE449174T1
ATE449174T1 AT07006224T AT07006224T ATE449174T1 AT E449174 T1 ATE449174 T1 AT E449174T1 AT 07006224 T AT07006224 T AT 07006224T AT 07006224 T AT07006224 T AT 07006224T AT E449174 T1 ATE449174 T1 AT E449174T1
Authority
AT
Austria
Prior art keywords
amino acid
new peptides
compound
activity
replaced
Prior art date
Application number
AT07006224T
Other languages
English (en)
Inventor
Kenji Kangawa
Masayasu Kojima
Hiroshi Hosoda
Hisayuki Matsuo
Yoshiharu Minamitake
Original Assignee
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenji Kangawa filed Critical Kenji Kangawa
Application granted granted Critical
Publication of ATE449174T1 publication Critical patent/ATE449174T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07006224T 1999-07-23 2000-07-24 Neue peptide ATE449174T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21000299 1999-07-23
JP33884199 1999-11-29
JP2000126623 2000-04-26

Publications (1)

Publication Number Publication Date
ATE449174T1 true ATE449174T1 (de) 2009-12-15

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00946453T ATE366813T1 (de) 1999-07-23 2000-07-24 Neue peptide
AT07006224T ATE449174T1 (de) 1999-07-23 2000-07-24 Neue peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00946453T ATE366813T1 (de) 1999-07-23 2000-07-24 Neue peptide

Country Status (16)

Country Link
US (5) US7385026B1 (de)
EP (3) EP1795598B1 (de)
JP (2) JP3471780B2 (de)
KR (1) KR100827973B1 (de)
CN (2) CN100506844C (de)
AT (2) ATE366813T1 (de)
AU (2) AU784035B2 (de)
BR (2) BR0012688A (de)
CA (2) CA2696819C (de)
CY (2) CY1107724T1 (de)
DE (2) DE60043361D1 (de)
DK (2) DK1795598T3 (de)
ES (3) ES2335235T3 (de)
IL (2) IL147652A0 (de)
PT (2) PT1197496E (de)
WO (1) WO2001007475A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147652A0 (en) * 1999-07-23 2002-08-14 Kangawa Kenji Novel peptides
EP1232175B1 (de) 1999-11-22 2009-07-08 ZymoGenetics, Inc. Methode zur bildung einen peptid-rezeptor komplex mit zsig33 polypeptiden.
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
US7141646B2 (en) 2000-05-12 2006-11-28 Kaneka Corporation Method of purifying vinyl polymer
EP1353683A4 (de) * 2000-05-30 2004-05-12 Merck & Co Inc Analoge von ghrelin
MXPA03000738A (es) * 2000-07-24 2003-06-04 Ardana Bioscience Ltd Antagonistas de grelina.
CN100491395C (zh) * 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
NZ537001A (en) * 2002-07-19 2007-04-27 Cytos Biotechnology Ag A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto
WO2004009616A2 (en) * 2002-07-23 2004-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Ghrelin analogs
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
EP1407779A1 (de) 2002-10-10 2004-04-14 Gastrotech A/S Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie
AU2004233705C1 (en) * 2003-04-30 2010-04-01 Kenji Kangawa Preventives or remedies for hepatopathy
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies
WO2005026211A2 (en) * 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
US20080269116A1 (en) * 2004-05-11 2008-10-30 Taub Dennis D Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
JP2008515771A (ja) * 2004-07-14 2008-05-15 イーライ リリー アンド カンパニー 抗グレリン抗体
EP1812044A2 (de) * 2004-10-27 2007-08-01 Gastrotech Pharma A/S Verwendung von wachstumshormon-sekretagoga bei der behandlung von personen mit nieren- und/oder leberinsuffizienz
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
US20080300180A1 (en) * 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
JP4843827B2 (ja) 2005-02-23 2011-12-21 国立大学法人京都大学 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
US7932231B2 (en) 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
KR20080082651A (ko) 2005-11-21 2008-09-11 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 데스아실 그렐린 및 그 유도체를 유효 성분으로 하는 피부수복 촉진 치료제
WO2007058359A1 (ja) * 2005-11-21 2007-05-24 University Of Miyazaki グレリン及びその誘導体又はＧＨＳ－Ｒ１ａに作用する物質を有効成分とする皮膚修復促進治療剤
EP2012809B1 (de) 2006-03-10 2013-05-22 Ipsen Pharma Verwendung eines ghrelin-agonisten zur erhöhung der katabolischen wirkung einer glukokortikoidbehandlung
US7981860B2 (en) 2006-03-13 2011-07-19 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
KR101510082B1 (ko) * 2006-08-01 2015-04-10 더 스크립스 리서치 인스티튜트 비만증을 억제하기 위한 백신 및 방법
EP2052738A1 (de) 2006-08-11 2009-04-29 University of Miyazaki Therapeutisches mittel zur beschleunigung der spinalnervenreparatur mit ghrelin, einem derivat davon oder einer substanz mit wirkung auf ghs-r1a als wirkstoff
WO2008018597A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci
NZ576470A (en) * 2006-09-27 2012-09-28 Ipsen Pharma Sas Analogs of ghrelin substituted at the n-terminal
BRPI0904622A2 (pt) 2008-05-23 2016-06-21 Asubio Pharma Co Ltd peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9078868B2 (en) 2010-01-15 2015-07-14 University Of Miyazaki Therapeutic agent for accelerating recovery of animal under medical treatment
US9315546B2 (en) * 2010-06-16 2016-04-19 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
WO2012117592A1 (ja) 2011-03-03 2012-09-07 国立大学法人宮崎大学 高体温治療剤
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
EP2849567B1 (de) 2012-05-17 2022-03-23 Extend Biosciences, Inc. Träger zur verbesserten arzneimittelabgabe
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN104853778A (zh) * 2012-10-24 2015-08-19 第一三共株式会社 用于肌萎缩性侧索硬化的治疗剂
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
TWI662967B (zh) * 2013-03-25 2019-06-21 日商志瑞亞新藥工業股份有限公司 食後期之胃運動亢進劑
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
CA3157605A1 (en) 2019-11-13 2021-05-20 Volker Schellenberger Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
CN120818010B (zh) * 2025-09-18 2025-12-05 天津科技大学 一种来自植物乳杆菌属细胞外囊泡的短肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CA2133834C (en) * 1992-04-07 2009-07-21 Stephen B.H. Kent Process for preparing modified proteins
EP0819137A1 (de) * 1995-03-31 1998-01-21 American Cyanamid Company Peptide mit wachstumsförndernder wirkung
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
BR9808059A (pt) * 1997-03-24 2000-03-08 Zimogenetics Inc Molécula de plinucleotìdeo isolada codificando um polipeptìdeo, polinucleotìdeo, vetor de expressão, célula cultivada, polipeptìdeo isolado, composição farmacêutica, anticorpo, processos para produzir polipeptìdeo zsig33, e, para estimular a motilidde gástrica
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1120846C (zh) * 1999-02-13 2003-09-10 中国人民解放军军事医学科学院基础医学研究所 生长激素释放肽及其应用
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
IL147652A0 (en) 1999-07-23 2002-08-14 Kangawa Kenji Novel peptides

Also Published As

Publication number Publication date
US8524871B2 (en) 2013-09-03
CN1362968A (zh) 2002-08-07
AU784035B2 (en) 2006-01-19
EP1795598A1 (de) 2007-06-13
US20110184153A1 (en) 2011-07-28
US20130172251A1 (en) 2013-07-04
ES2288151T3 (es) 2008-01-01
CN101693736A (zh) 2010-04-14
BR0012688A (pt) 2002-04-16
AU2006201580A1 (en) 2006-05-18
EP1795598B1 (de) 2009-11-18
KR100827973B1 (ko) 2008-05-21
DE60035502T2 (de) 2008-03-20
JP2004000251A (ja) 2004-01-08
CA2380058A1 (en) 2001-02-01
EP2119785B1 (de) 2013-03-13
US20100240866A1 (en) 2010-09-23
KR20020026543A (ko) 2002-04-10
DK1197496T3 (da) 2007-10-22
ES2401939T3 (es) 2013-04-25
US9573986B2 (en) 2017-02-21
CN100506844C (zh) 2009-07-01
IL147652A (en) 2010-04-29
US7385026B1 (en) 2008-06-10
PT1795598E (pt) 2010-01-05
PT1197496E (pt) 2007-08-29
ES2335235T3 (es) 2010-03-23
DE60043361D1 (de) 2009-12-31
DE60035502D1 (de) 2007-08-23
AU6023100A (en) 2001-02-13
CA2696819A1 (en) 2001-02-01
DK1795598T3 (da) 2010-02-01
IL147652A0 (en) 2002-08-14
BRPI0012688B1 (pt) 2018-06-05
US8227570B2 (en) 2012-07-24
JP4227857B2 (ja) 2009-02-18
US9938332B2 (en) 2018-04-10
AU2006201580B2 (en) 2009-01-08
EP1197496A1 (de) 2002-04-17
EP1197496B8 (de) 2007-10-03
CN101693736B (zh) 2020-09-11
EP1197496B1 (de) 2007-07-11
EP1197496A4 (de) 2002-11-20
CA2696819C (en) 2015-07-07
CY1109714T1 (el) 2014-08-13
BRPI0012688B8 (pt) 2021-05-25
US20090170763A1 (en) 2009-07-02
WO2001007475A1 (en) 2001-02-01
EP2119785A1 (de) 2009-11-18
ATE366813T1 (de) 2007-08-15
CY1107724T1 (el) 2013-04-18
CA2380058C (en) 2011-08-09
JP3471780B2 (ja) 2003-12-02

Similar Documents

Publication Publication Date Title
ATE449174T1 (de) Neue peptide
ATE458054T1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
DE69220861D1 (de) Zyklische Peptide und ihre Verwendung
RU94046091A (ru) Полипептидные антагонисты бомбезина, фармацевтическая композиция и способ лечения
EP0270214A3 (de) Vasopressinantagonisten
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
DE602004023827D1 (de) Ionenkanalaktivität hemmende niedrigmolekulare peptide
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE50307025D1 (de) Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp-antagonisten
GB0207644D0 (en) Peptides and their use
WO2003022300A1 (en) Preventives/remedies for bone/joint diseases
ATE354646T1 (de) Selektionsmarker
AU2003202489A1 (en) Screening method
ATE46173T1 (de) Pharmakologisch aktive peptide.
ATE417061T1 (de) Scorpionpeptid als blutdrucksenkendes mittel
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon
TH18962A (th) สารผสมที่ทำให้ขนร่วงซึ่งประกอบด้วยสารประกอบซัลฟ์ไฮดริล
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
AU2001277717A1 (en) Novel proteins and dnas thereof
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1795598

Country of ref document: EP